There is a fundamental gap in our understanding of the mechanism by which the highly pathogenic ebolaviruses (EBOV) and marburgviruses (MARV) enter their host cells and initiate infection. Our long-term objectives are to understand, in molecular detail, how these viruses exploit their host cells to gain entry into the cytoplasm, and to contribute to the development of antiviral therapies for EBOV/MARV infection. The focus of this particular application is the mechanism by which endosomal cysteine proteases, a class of cellular enzymes we identified to be essential EBOV/MARV entry host factors, activate GP to fuse viral and cellular bilayers. Our central hypothesis is that the proteolytic disassembly of GP within host cell endosomes, acting either alone or in concert with additional cellular stimuli, provides the """"""""trigger"""""""" signal that releases GP from its pre-fusion conformation and induces viral membrane fusion. Guided by strong preliminary data, we will test this hypothesis by pursuing two specific aims: 1. Identify the critical molecular features of GP proteolytic disassembly by endosomal cysteine proteases during EBOV and MARV entry 2. Reconstitute viral membrane fusion in vitro and elucidate the roles of proteases and non-protease host factors in fusion triggering

Public Health Relevance

Ebolaviruses and marburgviruses are the cause of an invariably fatal hemorrhagic fever in humans in equatorial Africa, and are also potential agents of bioterrorism. We expect this work to provide information crucial to the design and development of anti-EBOV/MARV therapies targeting cellular cysteine proteases. We also expect to find new targets, within the virus or the host cell, for developing antiviral drugs.

National Institute of Health (NIH)
National Institute of Allergy and Infectious Diseases (NIAID)
Research Project (R01)
Project #
Application #
Study Section
Virology - A Study Section (VIRA)
Program Officer
Repik, Patricia M
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Albert Einstein College of Medicine
Schools of Medicine
United States
Zip Code
Ndungo, Esther; Herbert, Andrew S; Raaben, Matthijs et al. (2016) A Single Residue in Ebola Virus Receptor NPC1 Influences Cellular Host Range in Reptiles. mSphere 1:
van der Linden, Wouter A; Schulze, Christopher J; Herbert, Andrew S et al. (2016) Cysteine Cathepsin Inhibitors as Anti-Ebola Agents. ACS Infect Dis 2:173-179
Spence, Jennifer S; Krause, Tyler B; Mittler, Eva et al. (2016) Direct Visualization of Ebola Virus Fusion Triggering in the Endocytic Pathway. MBio 7:e01857-15
Wec, Anna Z; Nyakatura, Elisabeth K; Herbert, Andrew S et al. (2016) A ""Trojan horse"" bispecific-antibody strategy for broad protection against ebolaviruses. Science 354:350-354
Frei, Julia C; Nyakatura, Elisabeth K; Zak, Samantha E et al. (2016) Bispecific Antibody Affords Complete Post-Exposure Protection of Mice from Both Ebola (Zaire) and Sudan Viruses. Sci Rep 6:19193
Bornholdt, Zachary A; Ndungo, Esther; Fusco, Marnie L et al. (2016) Host-Primed Ebola Virus GP Exposes a Hydrophobic NPC1 Receptor-Binding Pocket, Revealing a Target for Broadly Neutralizing Antibodies. MBio 7:e02154-15
Kleinfelter, Lara M; Jangra, Rohit K; Jae, Lucas T et al. (2015) Haploid Genetic Screen Reveals a Profound and Direct Dependence on Cholesterol for Hantavirus Membrane Fusion. MBio 6:e00801
Brojatsch, J├╝rgen; Lima Jr, Heriberto; Palliser, Deborah et al. (2015) Distinct cathepsins control necrotic cell death mediated by pyroptosis inducers and lysosome-destabilizing agents. Cell Cycle 14:964-72
Ng, Melinda; Ndungo, Esther; Kaczmarek, Maria E et al. (2015) Filovirus receptor NPC1 contributes to species-specific patterns of ebolavirus susceptibility in bats. Elife 4:
Koellhoffer, Jayne F; Dai, Zhou; Malashkevich, Vladimir N et al. (2014) Structural characterization of the glycoprotein GP2 core domain from the CAS virus, a novel arenavirus-like species. J Mol Biol 426:1452-68

Showing the most recent 10 out of 32 publications